Aspirin/MI Prevention Patient Identification Process Sought By FDA
This article was originally published in The Tan Sheet
Executive Summary
The practical application of risk assessment scores to identify appropriate patients for aspirin therapy as primary myocardial infarction prevention will be addressed during a Dec. 8 1advisory committee meeting